The stock of Catalyst Pharmaceuticals Inc (CPRX) has gone down by -4.03% for the week, with a -11.88% drop in the past month and a -12.96% drop in the past quarter. The volatility ratio for the week is 3.60%, and the volatility levels for the past 30 days are 3.21% for CPRX. The simple moving average for the past 20 days is -8.99% for CPRX’s stock, with a -2.04% simple moving average for the past 200 days.
Is It Worth Investing in Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Right Now?
The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is 13.97x, which is above its average ratio. Moreover, the 36-month beta value for CPRX is 0.69. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CPRX is 111.11M and currently, short sellers hold a 6.96% of that float. On June 27, 2025, CPRX’s average trading volume was 1.21M shares.
CPRX) stock’s latest price update
The stock of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has increased by 1.62 when compared to last closing price of 21.54. Despite this, the company has experienced a -4.03% fall in its stock price over the last five trading sessions. zacks.com reported 2025-06-26 that Catalyst (CPRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Robert W. Baird repeating the rating for CPRX by listing it as a “Outperform.” The predicted price for CPRX in the upcoming period, according to Robert W. Baird is $28 based on the research report published on February 04, 2025 of the current year 2025.
Stephens, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $35. The rating they have provided for CPRX stocks is “Overweight” according to the report published on November 18th, 2024.
Citigroup gave a rating of “Buy” to CPRX, setting the target price at $27 in the report published on March 14th of the previous year.
CPRX Trading at -8.20% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.64% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from Sundaram Preethi, who sale 2,324 shares at the price of $26.41 back on Jun 10 ’25. After this action, Sundaram Preethi now owns 42,681 shares of Catalyst Pharmaceuticals Inc, valued at $61,377 using the latest closing price.
Sundaram Preethi, the Chief Strategy Officer of Catalyst Pharmaceuticals Inc, sale 1,600 shares at $26.42 during a trade that took place back on Jun 11 ’25, which means that Sundaram Preethi is holding 41,081 shares at $42,272 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.43 for the present operating margin
- 0.83 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.37. The total capital return value is set at 0.29. Equity return is now at value 29.11, with 25.37 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 86.68.
Currently, EBITDA for the company is 232.9 million with net debt to EBITDA at -2.31. When we switch over and look at the enterprise to sales, we see a ratio of 3.91. The receivables turnover for the company is 7.4for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.14.
Conclusion
To wrap up, the performance of Catalyst Pharmaceuticals Inc (CPRX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
